Journal of Pharmaceutical Research

Open Access Open Access  Restricted Access Subscription Access

Case Series on Hemoglobin E-Beta-Thalassemia Major


Affiliations
1 Krupanidhi College of Pharmacy, 12/1 Chikka Bellandur, Carmelaram Post, Varthur Hobli, Bangalore - 560 035, Karnataka, India
2 Krupanidhi College of Pharmacy, 12/1 Chikka Bellandur, Carmelaram Post, Bangalore, India
 

Aim : The aim of case series is to describe the 3 Hemoglobin E ß-thalassemia cases, which are unique and requires special care and attention to diagnose/manage. Its natural history is little known, and also the reasons for their clinical diversity, or/and its management.

Presentation of case : 3 cases of transfusion dependent Hemoglobin E β -thalassemia major were included in the study. The patients reported similar complaints of weakness and delayed milestones. The patients were on regular red blood cell transfusion and iron chelation therapy from the age of 3 years. The beta-globin gene defects were defined in all the cases using similar techniques. Thalassemia mutation analysis by reverse clot blot testing showed a compound heterozygous for IVS 1-5 [G-C] and codon 26 [G-A] beta E mutation in the beta globin gene. Evaluation for iron overload showed severe cardiac iron deposit and severe hepatic iron deposit on MRI T2. During hospital stay, the patients received antibiotics and immune-suppressants in common.

Discussion & Conclusion : Patients are treated by lifelong blood transfusion every 15 to 30 days along with iron chelation therapy. Repetitive transfusions cause iron overload, with life-threatening complications, like such as cardiomyopathy, endocrine disorders, liver failures and, ultimately, premature death.Awareness, education and screening play the most important part in the prevention of life-threatening complications and control of thalassemia.


Keywords

Hb E/β Thalassemia, Transfusion Dependent, Hb E Mutation, Thalassemia Major.
User
Notifications
Font Size


  • Nadkarni A, GorakshakarA.C., LuC.Y., Krishnamoorthy R., Ghosh K, Roshan C, Mohanty D. Molecular Pathogenesis and Clinical Variability of â-Thalassemia Syndromes Among Indians. American Journal of Hematology.2001;68:75–80.

  • Mujawar Q, Ukkali S, Malagi N N, ThobbiA N.Haemoglobin E beta-Thalassemia.A case report from Bijapur, South India. Al Ameen J Med Sci. 2009;2 (1):82 84.

  • Dreuzy E, Bhukhai K, Leboulch P, Payen E. Current and future alternative therapies for beta-thalassemiamajor. Biomed J.2016;39(1):24-38.

  • Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/betathalassaemia: A common & clinically diverse disorder. Indian J Med Res, 2011;134, 522-531.

  • Oliveri NF. Treatment strategies for hemoglobin E betathalassemia. Blood Rev.2012;26 (1):28-30.

  • Galanello R, Raffaella O. Beta-thalassemia. Orphanet Journal of Rare Diseases.2010;5-11.


Abstract Views: 203

PDF Views: 120




  • Case Series on Hemoglobin E-Beta-Thalassemia Major

Abstract Views: 203  |  PDF Views: 120

Authors

Joice Samuel
Krupanidhi College of Pharmacy, 12/1 Chikka Bellandur, Carmelaram Post, Varthur Hobli, Bangalore - 560 035, Karnataka, India
Rajeswari Ramasamy
Krupanidhi College of Pharmacy, 12/1 Chikka Bellandur, Carmelaram Post, Bangalore, India

Abstract


Aim : The aim of case series is to describe the 3 Hemoglobin E ß-thalassemia cases, which are unique and requires special care and attention to diagnose/manage. Its natural history is little known, and also the reasons for their clinical diversity, or/and its management.

Presentation of case : 3 cases of transfusion dependent Hemoglobin E β -thalassemia major were included in the study. The patients reported similar complaints of weakness and delayed milestones. The patients were on regular red blood cell transfusion and iron chelation therapy from the age of 3 years. The beta-globin gene defects were defined in all the cases using similar techniques. Thalassemia mutation analysis by reverse clot blot testing showed a compound heterozygous for IVS 1-5 [G-C] and codon 26 [G-A] beta E mutation in the beta globin gene. Evaluation for iron overload showed severe cardiac iron deposit and severe hepatic iron deposit on MRI T2. During hospital stay, the patients received antibiotics and immune-suppressants in common.

Discussion & Conclusion : Patients are treated by lifelong blood transfusion every 15 to 30 days along with iron chelation therapy. Repetitive transfusions cause iron overload, with life-threatening complications, like such as cardiomyopathy, endocrine disorders, liver failures and, ultimately, premature death.Awareness, education and screening play the most important part in the prevention of life-threatening complications and control of thalassemia.


Keywords


Hb E/β Thalassemia, Transfusion Dependent, Hb E Mutation, Thalassemia Major.

References